A Phase II Study of AK112 With or Without AK117 for Patients With Metastatic Colorectal Cancer
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Ivonescimab (Primary) ; Ligufalimab (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Akeso Biopharma
Most Recent Events
- 27 Feb 2025 Number of treatment arms are increased from 6 to 11 by the addition of 5 more experimental treatment arms, namely- Expansion Stage Group C, D, E, F and G, Part 2 cohort 1 and Part 2 cohort 2.
- 27 Feb 2025 Planned number of patients changed from 104 to 254.
- 27 Feb 2025 Planned End Date changed from 25 Dec 2026 to 12 Aug 2028.